Influence of dopamine deficiency in early Parkinson's disease on the slow stimulation multifocal-ERG

被引:13
|
作者
Palmowski-Wolfe A.M. [1 ]
Perez M.T. [1 ,2 ]
Behnke S. [2 ]
Fuss G. [2 ]
Martziniak M. [2 ]
Ruprecht K.W. [1 ]
机构
[1] Department of Ophthalmology, University of Saarland
[2] Department of Neurology, University of Saarland
关键词
Dopamine; M-sequence; MfERG; Multifocal stimulation techniques; Parkinson;
D O I
10.1007/s10633-006-0008-8
中图分类号
学科分类号
摘要
Purpose: In animal studies intravitreal injection of tetrodotoxin (TTX) results in mfERG waveform changes similar to those observed in glaucoma. As TTX blocks amacrine as well as ganglion cells, there is still a question regarding the underlying cell population responsible for these changes in waveform. In an attempt to assess the contribution of the amacrine cells to these changes, a mfERG was obtained from patients with Parkinson's disease as some amacrine cells are mediated by dopamine, a substance lacking in Parkinson's. Methods: Eight patients with early Parkinson's disease underwent ophthalmologic examination, testing of contrast sensitivity and electrophysiological examination according to ISCEV standard at least 12 h following their last medication with Dopamine. A slow stimulation mfERG was obtained with a stimulus base interval of 53.3 ms and with a stimulus base interval of 106.6 ms. During MF-ERG recordings 103 hexagons stimulated the central 50 deg of the retina simultaneously and independently (m-sequence 213, Lmax: 200 cd/m2,-100% contrast). Results: Contrast sensitivity and ISCEV standard electrophysiological testing was unremarkable. When the mfERG was analyzed, only four patients had an adequate signal-to-noise ratio to allow further data analysis - one of whom was diagnosed with a multi system atrophy in retrospect. The first order response component was analyzed at a filter setting of 10-300 Hz and at 100-300 Hz (OPs) and compared to mfERGs of a control group. On average, in patients, the amplitude of N1P1 was slightly lower in the central and nasal response averages. When the three OPs at a latency of 72-89 ms were analyzed in the 53.3 ms base interval recording, the most marked difference in amplitude was observed in the superior nasal response average of the first OP. Here a mean amplitude of 1.3 nV/deg2 in patients compared to a mean amplitude of 1.9 nV/deg2 in the control group (P: 0.08). Discussion: In contrast to our previous findings in NTG, there was a consistent presence of three OPs. Under the stimulus conditions applied, we did not find an influence of dopaminergic amacrine cells on the mfERG in our patients with moderate stages of Parkinsion's. The difficulties in obtaining an adequate signal-to noise ratio due to e.g. muscle artifacts even in Parkinson patients of moderate disease stages render a success of mfERG recording in patients with more advanced stages unlikely. The question of the influence of dopaminergic amacrine cells on the mfERG could possibly be addressed using MPDT in animal research. © Springer 2006.
引用
收藏
页码:209 / 215
页数:6
相关论文
共 50 条
  • [31] Levodopa Versus Dopamine Agonist After Subthalamic Stimulation in Parkinson's Disease
    Picillo, Marina
    Phokaewvarangkul, Onanong
    Poon, Yu-Yan
    McIntyre, Cameron C.
    Beylergil, Sinem Balta
    Munhoz, Renato P.
    Kalia, Suneil K.
    Hodaie, Mojgan
    Lozano, Andres M.
    Fasano, Alfonso
    MOVEMENT DISORDERS, 2021, 36 (03) : 672 - 680
  • [32] DOPAMINE DYSREGULATION SYNDROME AND DEEP BRAIN STIMULATION IN PATIENTS WITH PARKINSON'S DISEASE
    Omarova, S.
    Fedorova, N.
    Tomskiy, A.
    Gamaleya, A.
    Brill, E.
    PARKINSONISM & RELATED DISORDERS, 2018, 46 : E85 - E85
  • [33] Pathophysiology of Parkinson's disease. Continuous dopamine stimulation: origin and reality
    Obeso-Inchausti, Jose A.
    REVISTA DE NEUROLOGIA, 2010, 50 : S26 - S26
  • [34] Dopamine Receptor Agonists for the Treatment of Early or Advanced Parkinson's Disease
    Perez-Lloret, Santiago
    Rascol, Olivier
    CNS DRUGS, 2010, 24 (11) : 941 - 968
  • [35] Dopamine agonists in Parkinson's disease - What is their role in early treatment?
    Stocchi, F
    CNS DRUGS, 1998, 10 (03) : 159 - 170
  • [36] Role of dopamine receptor agonists in the treatment of early Parkinson's disease
    Bonuccelli, Ubaldo
    Del Dotto, Paolo
    Rascol, Olivier
    PARKINSONISM & RELATED DISORDERS, 2009, 15 : S44 - S53
  • [37] Predictors of dopamine dysregulation syndrome in patients with early Parkinson’s disease
    Keke Liang
    Xiaohuan Li
    Jianjun Ma
    Hongqi Yang
    Xiaoxue Shi
    Yongyan Fan
    Dawei Yang
    Dashuai Guo
    Chuanze Liu
    Linrui Dong
    Qingqing Chang
    Qi GU
    Siyuan Chen
    Dongsheng Li
    Neurological Sciences, 2023, 44 : 4333 - 4342
  • [38] Predictors of dopamine dysregulation syndrome in patients with early Parkinson's disease
    Liang, Keke
    Li, Xiaohuan
    Ma, Jianjun
    Yang, Hongqi
    Shi, Xiaoxue
    Fan, Yongyan
    Yang, Dawei
    Guo, Dashuai
    Liu, Chuanze
    Dong, Linrui
    Chang, Qingqing
    Gu, Qi
    Chen, Siyuan
    Li, Dongsheng
    NEUROLOGICAL SCIENCES, 2023, 44 (12) : 4333 - 4342
  • [39] Striatopallidal changes in early Parkinson's disease - Partial dopamine depletions
    Grissell, AE
    Ariano, MA
    BASAL GANGLIA VIII, 2005, 56 : 295 - 305
  • [40] Dopamine Receptor Agonists for the Treatment of Early or Advanced Parkinson’s Disease
    Santiago Perez-Lloret
    Olivier Rascol
    CNS Drugs, 2010, 24 : 941 - 968